Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

BOTHELL, Wash., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ALDR, a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Robert W. Azelby, Alder's president and chief executive officer, at each of the following upcoming healthcare conferences:

• Wells Fargo 2018 Healthcare Conference at 9:45 a.m. ET on Thursday, September 6, 2018 in Boston, MA.
• Morgan Stanley 16^th Annual Global Healthcare Conference at 5:15 p.m. ET on Thursday, September 13, 2018 in New York, NY.

A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after each live event concludes.

• Wells Fargo Link: https://cc.talkpoint.com/well001/090518a_as/?entity=63_77EV60U
• Morgan Stanley Link: https://cc.talkpoint.com/morg007/091218a_as/?entity=78_7G4PHJ2

About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder's lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.

Investor Relations Contact:                                        
Michael Schaffzin
Stern Investor Relations, Inc.
212.362.1200
michael@sternir.com

Media Contact: 
Ashley Cadle
TogoRun
a.cadle@togorun.com
310.463.0143